FRMO CORP
FRMO
Argo Blockchain
ARBK
BIT Mining
BTCM
The9 Ltd
NCTY
Digihost Technology
DGHI
US Stock MarketDetailed Quotes
MRSN Mersana Therapeutics
- 0.415
- -0.033-7.39%
Trading Mar 26 11:19 ET
51.72MMarket Cap-0.74P/E (TTM)
0.450High0.413Low634.78KVolume0.450Open0.448Pre Close267.88KTurnover0.79%Turnover RatioLossP/E (Static)124.63MShares4.64052wk High-5.46P/B33.17MFloat Cap0.40552wk Low--Dividend TTM79.93MShs Float29.090Historical High--Div YieldTTM8.26%Amplitude0.405Historical Low0.422Avg Price1Lot Size
Market Insights
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Mersana Therapeutics Stock Forum
Mersana's clinical progress with Emi-Le (emiltatug ledadotin) represents a significant development in the B7-H4-targeted ADC landscape. The initial Phase 1 data from 130 patients shows promising activity across multiple tumor types, with particular emphasis on heavily pretreated triple-negative breast cancer (TNBC)—an area with substantial unmet medical need.
The expansion cohort at 67.4 mg/m² administered every four weeks in TNBC patient...
Mersana's Q4 and full-year 2024 results illustrate a significant financial improvement amid promising clinical developments. Their net loss narrowed substantially to $69.2 million ($0.56/share) for 2024, down from $171.7 million ($1.48/share) in 2023. This 59.7% reduction reflects successful restructuring efforts and strategic pipeline focus.
The company reported Q4 collaboration revenue of $16.4 million, up 53.3% from the year-ago period, drive...
Mersana's ADC Pipeline Advances: FDA Fast Track Designation as Q4 Losses Narrow
What is Mersana Therapeutics' (MRSN) main focus in cancer treatment?
Mersana Therapeutics focuses on discovering and developing antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need.
Exclusive: Mersana Therapeutics CEO to Reveal ADC Pipeline Updates at Guggenheim Conference
Citi recently initiated coverage on Mersana Therapeutics with a Buy rating, spotlighting the potential of the company's XMT-1660 project. The firm's coverage transfer to analyst Yigal Nochomovitz comes with optimistic expectations for the XMT-1660 data. This upcoming data is seen as a significant catalyst that could revitalize interest in the company's shares.
On the clinical front, Mersana's XMT-1660 h...
No comment yet